Le Lézard
Classified in: Health
Subjects: CCA, PET, ANW

Heska First Quarter 2022 Financial Results and Earnings Call Scheduled for May 9, 2022


LOVELAND, Colo., April 18, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, will report its first quarter 2022 financial performance in a press release before the market opens on Monday, May 9, 2022. The Company will also host an earnings call at 9 a.m. MT / 11 a.m. ET to discuss the results.

To access the conference call:
    From within the United States, please dial 1-800-239-9838
    From outside of the United States, please dial 1-323-794-2551
    Reference Conference ID: 6552107

The earnings call will be webcast live from the Company's investor relations website at  Heska First Quarter 2022 Earnings Call Webcast.

A telephonic replay will be available at 2 p.m. ET on May 9 through 11:59 p.m. ET on May 23, 2022 and the webcast will be archived on the Company's website for 90 days.

To access the replay by telephone:
    From within the United States, please dial 1-844-512-2921
    From outside the United States, please dial 1-412-317-6671
    Reference Replay Pin Number: 6552107

About Heska
Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostics, informatics, and specialty healthcare solutions through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production for third-parties, primarily for herd animal health. For more information, please visit www.heska.com.

 

SOURCE Heska Corporation


These press releases may also interest you

18 aoû 2022
Nuance Pharma ("the Company") announces the Center for Drug Evaluation ("CDE") has approved its Investigational New Drug ("IND") application supporting its pivotal clinical trial of Ensifentrine for the maintenance treatment of chronic obstructive...

18 aoû 2022
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelmatm (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced...

18 aoû 2022
Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Company has completed the subject enrollment and dosing for the comparative Phase II clinical trial between its...

18 aoû 2022
The global homecare oxygen concentrators market size is expected to grow by USD 1.21 billion between 2020 and 2025. The market witnessed a YOY growth of 14.83% in 2021 and the growth momentum is expected to accelerate at a CAGR of about 15% during...

18 aoû 2022
The "Ophthalmic Lens Market by Product and Geography - Forecast and Analysis 2021-2025" report by Technavio expects the market size to grow by USD 11.80 billion between 2020 and 2025. The market witnessed a YOY growth of 4.03% in 2021 and the growth...

18 aoû 2022
Accelerate Diagnostics, Inc. ("Accelerate Diagnostics") today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds to Accelerate Diagnostics...



News published on 18 april 2022 at 08:00 and distributed by: